30€
60€
100€
150€

Home>News>Decree “advanced therapy medicinal products”: a new milestone for the AFM-Telethon and laboratory Genethon!

08 Nov 2012

Decree “advanced therapy medicinal products”: a new milestone for the AFM-Telethon and laboratory Genethon!

With this decree, Genethon will be able to accelerate the production of gene therapy for human trials through its center, Genethon Bioprod, which has the largest capacity in the world in this field.

The decree relating to “advanced therapy medicinal products” was published in the Journal Officiel on 8 November. A decree awaited since the adoption of the Law of 22 March 2011 allowing organizations to become non-profit pharmaceutical establishments. In the coming days, Genethon submit its application for accreditation by the National Security Agency of the drug (MSNA).

20 Mar 2018

The 31th Telethon edition reaches a final collection of 89,189,384 euros

On 8th and 9th December 2017, the Telethon enthralled the public throughout France.

14 Mar 2018

Spinal muscular atrophy : AveXis enters into licensing agreement with Genethon

AveXis, Inc. and Genethon today announced they have entered into an exclusive, worldwide license agreement for in vivo gene therapy delivery of AAV9 vector into the central nervous system (CNS) for the treatment of spinal muscular atrophy (SMA).

13 Feb 2018

Gene therapy: Généthon starts a clinical trial to test a gene therapy treatment for a rare liver disease, Crigler-Najjar Syndrome

Illustration for news: Gene therapy: Généthon starts a clinical trial to test a gene therapy treatment for a rare liver disease, Crigler-Najjar Syndrome

Généthon, a laboratory created by AFM-Téléthon, starts a European phase I/II clinical trial to test a treatment for Crigler-Najjar Syndrome, a rare liver disease.

All the news